
Kamada (KMDA) Stock Forecast & Price Target
Kamada (KMDA) Analyst Ratings
Bulls say
Kamada Ltd is projected to report revenues of $43.5 million for 2Q25, marking a 7% annual increase, with earnings per share expected to rise to $0.08 from $0.07 year-over-year. The anticipated revenue growth is attributed to an ongoing increase in sales of proprietary products in the U.S., the launch of new biosimilars in Israel, and sustained shipments of Kamrab and Varizig to Latin America under a significant three-year contract established in January 2025. This strong financial performance is further underscored by a substantial 19% revenue growth in 1Q25, primarily driven by heightened sales of proprietary products such as Glassia and Kamrab, along with royalty income.
Bears say
Kamada Ltd has faced challenges that have negatively impacted its financial performance, particularly within its Proprietary Products segment, which is the primary source of revenue. The company has reported a decline in sales for its key products, raising concerns about its ability to maintain market traction and profitability. Additionally, increased operational costs and competitive pressures in the therapeutic landscape have further strained the company’s financial outlook.
This aggregate rating is based on analysts' research of Kamada and is not a guaranteed prediction by Public.com or investment advice.
Kamada (KMDA) Analyst Forecast & Price Prediction
Start investing in Kamada (KMDA)
Order type
Buy in
Order amount
Est. shares
0 shares